Current therapeutic approaches in patients with brain metastases

The development of brain metastases is often viewed as the end stage of a disease course and engenders skepticism about the efficacy of treatment. Aggressive management of brain metastases is effective in both symptom palliation and the prolongation of life. The majority of patients with controlled...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current treatment options in oncology 2006-11, Vol.7 (6), p.479-489
Hauptverfasser: Peacock, Kevin H, Lesser, Glenn J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 489
container_issue 6
container_start_page 479
container_title Current treatment options in oncology
container_volume 7
creator Peacock, Kevin H
Lesser, Glenn J
description The development of brain metastases is often viewed as the end stage of a disease course and engenders skepticism about the efficacy of treatment. Aggressive management of brain metastases is effective in both symptom palliation and the prolongation of life. The majority of patients with controlled intracranial metastases will expire from systemic disease rather than from recurrence of these metastases. Single brain metastases should be treated with surgical resection or stereotactic radiosurgery, though it is unclear at this time if one modality is more effective than the other. Surgical resection is preferred when a pathologic diagnosis is needed, for tumors larger than 3.5 cm, or when immediate tumor mass decompression is required. Stereotactic radiosurgery (SRS) should be applied for single tumors less than 3.5 cm in surgically inaccessible areas and for patients who are not surgical candidates. Small tumors (ie, < 3.5 cm) that cause minimal edema and are surgically accessible may be treated with either surgery or SRS. There is controversy over whether whole brain radiation therapy (WBRT) can be omitted following surgical resection or SRS. Omission of WBRT increases intracranial tumor recurrence; however, this has not been correlated with decreased survival. Clinicians who choose to omit upfront WBRT are obligated to monitor the patient closely for intracranial recurrence, at which time further salvage therapy in the form of surgery, SRS, or WBRT may be considered. Histology is of particular importance when considering WBRT for patients with radioresistant tumors such as melanoma, renal cell carcinoma, or sarcoma. WBRT may be of less clinical benefit in this setting. Chemotherapy has been demonstrated to improve response rates when used as an adjunct to radiation therapy. These improvements in response rates have not been correlated with an improvement in median survival. Noncytotoxic radiosensitizing agents such as motexafin and efaproxiral show promise. Phase III trials to assess the benefit of motexafin in patients with metastatic lung cancer and efaproxiral in patients with metastatic breast cancer are ongoing. Targeted therapies offer promise in achieving therapeutic efficacy while minimizing side effects. Surgical adjuncts such as BCNU (carmustine) wafers and the GliaSite Radiation System (Cytyc Corporation, Marlborough, MA) may be useful in the future in achieving optimal local tumor control.
doi_str_mv 10.1007/s11864-006-0023-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68945420</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68945420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c270t-ff53e93e08dfe10ac28877c4c5927710e95196511f77eac64a02787a2dd25e5b3</originalsourceid><addsrcrecordid>eNp9kUtLAzEUhYMotlZ_gBsZENyN5mbymp1SfEHBja5DmrlDp3QeJhnEf2-GFgQXwg03hC-HwzmEXAK9BUrVXQDQkueUynRYkesjMgdR8FwypY6nO1M5U6yckbMQtokRnJanZAaKFkxIOif3y9F77GIWN-jtgGNsXGaHwffWbTBkTZcNNjaJCNlXEzfZ2tv01mK0IQ2Gc3JS213Ai8NekI-nx_flS756e35dPqxyxxSNeV2LAssCqa5qBGod01opx50ok1egWAoopQColULrJLeUKa0sqyomUKyLBbnZ6yZrnyOGaNomONztbIf9GIzUJRec0QRe_wG3_ei75M0wKbmWKTr9HwUAhWaUaZEo2FPO9yF4rM3gm9b6bwPUTBWYfQUmVWCmCsykfHVQHtctVr8_DpkXP8Uaf3k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1113820285</pqid></control><display><type>article</type><title>Current therapeutic approaches in patients with brain metastases</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Peacock, Kevin H ; Lesser, Glenn J</creator><creatorcontrib>Peacock, Kevin H ; Lesser, Glenn J</creatorcontrib><description>The development of brain metastases is often viewed as the end stage of a disease course and engenders skepticism about the efficacy of treatment. Aggressive management of brain metastases is effective in both symptom palliation and the prolongation of life. The majority of patients with controlled intracranial metastases will expire from systemic disease rather than from recurrence of these metastases. Single brain metastases should be treated with surgical resection or stereotactic radiosurgery, though it is unclear at this time if one modality is more effective than the other. Surgical resection is preferred when a pathologic diagnosis is needed, for tumors larger than 3.5 cm, or when immediate tumor mass decompression is required. Stereotactic radiosurgery (SRS) should be applied for single tumors less than 3.5 cm in surgically inaccessible areas and for patients who are not surgical candidates. Small tumors (ie, &lt; 3.5 cm) that cause minimal edema and are surgically accessible may be treated with either surgery or SRS. There is controversy over whether whole brain radiation therapy (WBRT) can be omitted following surgical resection or SRS. Omission of WBRT increases intracranial tumor recurrence; however, this has not been correlated with decreased survival. Clinicians who choose to omit upfront WBRT are obligated to monitor the patient closely for intracranial recurrence, at which time further salvage therapy in the form of surgery, SRS, or WBRT may be considered. Histology is of particular importance when considering WBRT for patients with radioresistant tumors such as melanoma, renal cell carcinoma, or sarcoma. WBRT may be of less clinical benefit in this setting. Chemotherapy has been demonstrated to improve response rates when used as an adjunct to radiation therapy. These improvements in response rates have not been correlated with an improvement in median survival. Noncytotoxic radiosensitizing agents such as motexafin and efaproxiral show promise. Phase III trials to assess the benefit of motexafin in patients with metastatic lung cancer and efaproxiral in patients with metastatic breast cancer are ongoing. Targeted therapies offer promise in achieving therapeutic efficacy while minimizing side effects. Surgical adjuncts such as BCNU (carmustine) wafers and the GliaSite Radiation System (Cytyc Corporation, Marlborough, MA) may be useful in the future in achieving optimal local tumor control.</description><identifier>ISSN: 1527-2729</identifier><identifier>EISSN: 1534-6277</identifier><identifier>EISSN: 1534-5277</identifier><identifier>DOI: 10.1007/s11864-006-0023-8</identifier><identifier>PMID: 17032560</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Brain cancer ; Brain Neoplasms - pathology ; Brain Neoplasms - therapy ; Breast cancer ; Chemotherapy ; Clinical trials ; Combined Modality Therapy ; Decompression ; Edema ; Humans ; Kidney cancer ; Lung cancer ; Medical research ; Melanoma ; Metastases ; Metastasis ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - therapy ; Palliation ; Patients ; Radiation therapy ; Radiosurgery ; Renal cell carcinoma ; Response rates ; Salvage Therapy ; Sarcoma ; Stereotaxic Techniques ; Surgery ; Tumors</subject><ispartof>Current treatment options in oncology, 2006-11, Vol.7 (6), p.479-489</ispartof><rights>Current Science Inc. 2006</rights><rights>Current Science Inc 2006.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c270t-ff53e93e08dfe10ac28877c4c5927710e95196511f77eac64a02787a2dd25e5b3</citedby><cites>FETCH-LOGICAL-c270t-ff53e93e08dfe10ac28877c4c5927710e95196511f77eac64a02787a2dd25e5b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17032560$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peacock, Kevin H</creatorcontrib><creatorcontrib>Lesser, Glenn J</creatorcontrib><title>Current therapeutic approaches in patients with brain metastases</title><title>Current treatment options in oncology</title><addtitle>Curr Treat Options Oncol</addtitle><description>The development of brain metastases is often viewed as the end stage of a disease course and engenders skepticism about the efficacy of treatment. Aggressive management of brain metastases is effective in both symptom palliation and the prolongation of life. The majority of patients with controlled intracranial metastases will expire from systemic disease rather than from recurrence of these metastases. Single brain metastases should be treated with surgical resection or stereotactic radiosurgery, though it is unclear at this time if one modality is more effective than the other. Surgical resection is preferred when a pathologic diagnosis is needed, for tumors larger than 3.5 cm, or when immediate tumor mass decompression is required. Stereotactic radiosurgery (SRS) should be applied for single tumors less than 3.5 cm in surgically inaccessible areas and for patients who are not surgical candidates. Small tumors (ie, &lt; 3.5 cm) that cause minimal edema and are surgically accessible may be treated with either surgery or SRS. There is controversy over whether whole brain radiation therapy (WBRT) can be omitted following surgical resection or SRS. Omission of WBRT increases intracranial tumor recurrence; however, this has not been correlated with decreased survival. Clinicians who choose to omit upfront WBRT are obligated to monitor the patient closely for intracranial recurrence, at which time further salvage therapy in the form of surgery, SRS, or WBRT may be considered. Histology is of particular importance when considering WBRT for patients with radioresistant tumors such as melanoma, renal cell carcinoma, or sarcoma. WBRT may be of less clinical benefit in this setting. Chemotherapy has been demonstrated to improve response rates when used as an adjunct to radiation therapy. These improvements in response rates have not been correlated with an improvement in median survival. Noncytotoxic radiosensitizing agents such as motexafin and efaproxiral show promise. Phase III trials to assess the benefit of motexafin in patients with metastatic lung cancer and efaproxiral in patients with metastatic breast cancer are ongoing. Targeted therapies offer promise in achieving therapeutic efficacy while minimizing side effects. Surgical adjuncts such as BCNU (carmustine) wafers and the GliaSite Radiation System (Cytyc Corporation, Marlborough, MA) may be useful in the future in achieving optimal local tumor control.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - therapy</subject><subject>Breast cancer</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Decompression</subject><subject>Edema</subject><subject>Humans</subject><subject>Kidney cancer</subject><subject>Lung cancer</subject><subject>Medical research</subject><subject>Melanoma</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Palliation</subject><subject>Patients</subject><subject>Radiation therapy</subject><subject>Radiosurgery</subject><subject>Renal cell carcinoma</subject><subject>Response rates</subject><subject>Salvage Therapy</subject><subject>Sarcoma</subject><subject>Stereotaxic Techniques</subject><subject>Surgery</subject><subject>Tumors</subject><issn>1527-2729</issn><issn>1534-6277</issn><issn>1534-5277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtLAzEUhYMotlZ_gBsZENyN5mbymp1SfEHBja5DmrlDp3QeJhnEf2-GFgQXwg03hC-HwzmEXAK9BUrVXQDQkueUynRYkesjMgdR8FwypY6nO1M5U6yckbMQtokRnJanZAaKFkxIOif3y9F77GIWN-jtgGNsXGaHwffWbTBkTZcNNjaJCNlXEzfZ2tv01mK0IQ2Gc3JS213Ai8NekI-nx_flS756e35dPqxyxxSNeV2LAssCqa5qBGod01opx50ok1egWAoopQColULrJLeUKa0sqyomUKyLBbnZ6yZrnyOGaNomONztbIf9GIzUJRec0QRe_wG3_ei75M0wKbmWKTr9HwUAhWaUaZEo2FPO9yF4rM3gm9b6bwPUTBWYfQUmVWCmCsykfHVQHtctVr8_DpkXP8Uaf3k</recordid><startdate>200611</startdate><enddate>200611</enddate><creator>Peacock, Kevin H</creator><creator>Lesser, Glenn J</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200611</creationdate><title>Current therapeutic approaches in patients with brain metastases</title><author>Peacock, Kevin H ; Lesser, Glenn J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c270t-ff53e93e08dfe10ac28877c4c5927710e95196511f77eac64a02787a2dd25e5b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - therapy</topic><topic>Breast cancer</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Decompression</topic><topic>Edema</topic><topic>Humans</topic><topic>Kidney cancer</topic><topic>Lung cancer</topic><topic>Medical research</topic><topic>Melanoma</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Palliation</topic><topic>Patients</topic><topic>Radiation therapy</topic><topic>Radiosurgery</topic><topic>Renal cell carcinoma</topic><topic>Response rates</topic><topic>Salvage Therapy</topic><topic>Sarcoma</topic><topic>Stereotaxic Techniques</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peacock, Kevin H</creatorcontrib><creatorcontrib>Lesser, Glenn J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Current treatment options in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peacock, Kevin H</au><au>Lesser, Glenn J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current therapeutic approaches in patients with brain metastases</atitle><jtitle>Current treatment options in oncology</jtitle><addtitle>Curr Treat Options Oncol</addtitle><date>2006-11</date><risdate>2006</risdate><volume>7</volume><issue>6</issue><spage>479</spage><epage>489</epage><pages>479-489</pages><issn>1527-2729</issn><eissn>1534-6277</eissn><eissn>1534-5277</eissn><abstract>The development of brain metastases is often viewed as the end stage of a disease course and engenders skepticism about the efficacy of treatment. Aggressive management of brain metastases is effective in both symptom palliation and the prolongation of life. The majority of patients with controlled intracranial metastases will expire from systemic disease rather than from recurrence of these metastases. Single brain metastases should be treated with surgical resection or stereotactic radiosurgery, though it is unclear at this time if one modality is more effective than the other. Surgical resection is preferred when a pathologic diagnosis is needed, for tumors larger than 3.5 cm, or when immediate tumor mass decompression is required. Stereotactic radiosurgery (SRS) should be applied for single tumors less than 3.5 cm in surgically inaccessible areas and for patients who are not surgical candidates. Small tumors (ie, &lt; 3.5 cm) that cause minimal edema and are surgically accessible may be treated with either surgery or SRS. There is controversy over whether whole brain radiation therapy (WBRT) can be omitted following surgical resection or SRS. Omission of WBRT increases intracranial tumor recurrence; however, this has not been correlated with decreased survival. Clinicians who choose to omit upfront WBRT are obligated to monitor the patient closely for intracranial recurrence, at which time further salvage therapy in the form of surgery, SRS, or WBRT may be considered. Histology is of particular importance when considering WBRT for patients with radioresistant tumors such as melanoma, renal cell carcinoma, or sarcoma. WBRT may be of less clinical benefit in this setting. Chemotherapy has been demonstrated to improve response rates when used as an adjunct to radiation therapy. These improvements in response rates have not been correlated with an improvement in median survival. Noncytotoxic radiosensitizing agents such as motexafin and efaproxiral show promise. Phase III trials to assess the benefit of motexafin in patients with metastatic lung cancer and efaproxiral in patients with metastatic breast cancer are ongoing. Targeted therapies offer promise in achieving therapeutic efficacy while minimizing side effects. Surgical adjuncts such as BCNU (carmustine) wafers and the GliaSite Radiation System (Cytyc Corporation, Marlborough, MA) may be useful in the future in achieving optimal local tumor control.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>17032560</pmid><doi>10.1007/s11864-006-0023-8</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1527-2729
ispartof Current treatment options in oncology, 2006-11, Vol.7 (6), p.479-489
issn 1527-2729
1534-6277
1534-5277
language eng
recordid cdi_proquest_miscellaneous_68945420
source MEDLINE; SpringerLink Journals
subjects Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Brain cancer
Brain Neoplasms - pathology
Brain Neoplasms - therapy
Breast cancer
Chemotherapy
Clinical trials
Combined Modality Therapy
Decompression
Edema
Humans
Kidney cancer
Lung cancer
Medical research
Melanoma
Metastases
Metastasis
Neoplasm Metastasis
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - therapy
Palliation
Patients
Radiation therapy
Radiosurgery
Renal cell carcinoma
Response rates
Salvage Therapy
Sarcoma
Stereotaxic Techniques
Surgery
Tumors
title Current therapeutic approaches in patients with brain metastases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T11%3A06%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20therapeutic%20approaches%20in%20patients%20with%20brain%20metastases&rft.jtitle=Current%20treatment%20options%20in%20oncology&rft.au=Peacock,%20Kevin%20H&rft.date=2006-11&rft.volume=7&rft.issue=6&rft.spage=479&rft.epage=489&rft.pages=479-489&rft.issn=1527-2729&rft.eissn=1534-6277&rft_id=info:doi/10.1007/s11864-006-0023-8&rft_dat=%3Cproquest_cross%3E68945420%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1113820285&rft_id=info:pmid/17032560&rfr_iscdi=true